Primäre und sekundäre glomeruläre Erkrankungen

Schlüsselwörter

membranoproliferative Glomerulonephritis - membranöse Glomerulonephritis - kryoglobulinämische Vaskulitis - Lupus-Nephritis - hämolytisch-urämisches Syndrom - Eculizumab

Keywords

membranoproliferative glomerulonephritis - membranous nephropathy - cryoglobulinemic vasculitis and glomerulonephritis - lupus nephritis - hemolytic-uremic syndrome - eculizumab

• Literatur

• 1 Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992; 327: 1490-1495
• 2 Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol 2010; 25: 1409-1418
• 3 Beck Jr LH, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361: 11-21
• 4 Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; Mar 8. [Epub ahead of print]
• 5 Chatelet V, Frémeaux-Bacchi V, Lobbedez T et al. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 9: 2644-2645
• 6 D'Cruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet 2007; 369: 587-596
• 7 De Vita S, De Re V, Gasparotto D et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 2000; 43: 94-102
• 8 De Vita S, Quartuccio L, Isola M et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 843-853
• 9 Debiec H, Lefeu F, Kemper MJ et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 2011; 364: 2101-2110 Erratum in: N Engl J Med 2011; 365: 477
• 10 Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895
• 11 Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 544-546
• 12 Houssiau FA, D'Cruz D, Sangle S et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69: 2083-2089
• 13 Kamanamool N, McEvoy M, Attia J et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore) 2010; 89: 227-235
• 14 Kaplan M. Eculizumab (Alexion). Curr Opin Investig Drugs 2002; 3: 1017-1023
• 15 Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364: 2561-2563
• 16 Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-544
• 17 Pickering M, Cook HT. Complement and glomerular disease: new insights. Curr Opin Nephrol Hypertens 2011; 20: 271-277
• 18 Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64: 835-842
• 19 Stahl RA, Hoxha E, Helmchen U. Membranöse Glomerulonephritis: Differenziertere Therapien durch Autoantikörperbestimmung?. Dtsch Med Wochenschr 2011; 136: 1733-1737
• 20 Stanescu HC, Arcos-Burgos M, Medlar A et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364: 616-626
• 21 Zimmerhackl LB, Hofer J, Cortina G et al. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362: 1746-1748